As a result of the significant disruption that is being caused by the COVID-19 pandemic, we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.
Announcement: COVID-19 impact on peer-review
BMC Cardiovascular Disorders is pleased to welcome submissions to this thematic series. All work highlighting current progress and challenges in the diagnosis and treatment of cardiovascular disorders will be considered.
We are recruiting new Associate Editors to join our international Editorial Board, helping to provide expertise on a wide range of subjects within the area of disorders of the heart and circulatory system
Perhaps the outcome was unexpected? Or maybe you haven't had a chance to analyse it? Or it just didn't make it into the final paper?
Interesting data often gets overlooked. By publishing it as a data note in BMC Research Notes it can be found in PubMed, SCImago, Scopus and other indexing services.
Find out which formats we accept and how easy it is to free your data.
The editors and staff of BMC Cardiovascular Disorders would like to warmly thank the reviewers whose comments helped to shape the journal, for their invaluable assistance with review of manuscripts in Volume 18 (2018).
Aims and scope
Read the published content in this thematic series covering all aspects of research into Sudden Cardiac Death from next-generation sequencing methods to eHealth-based interventions.
Ciarán Martin Fitzpatrick, BioMed Central, UK
- Tianxiao Huan, National Institutes of Health, USA
- Michel Noutsias, University Hospital of Jena, DE
- Barry Palmer, University of Otago, NZ
Sarah Gray, BioMed Central, UK
Click here to view which Articles have been shared the most in the last month!
Dr. Huan has been working in the Population Sciences Branch, Framingham Heart Study, and National Heart, Lung and Blood Institute (NHLBI), USA, for nearly a decade using high throughput genetics and multi-omics data